Osteoporosis care gets personal as zoledronate stays underused and romosozumab safety data emerge

Osteoporosis is common in aging adults, yet many people at high risk for fracture are never treated. Fractures, especially of the hip, carry heavy costs in disability, loss of independence, and mortality, so improving risk assessment and treatment uptake is a core longevity concern.

This article is a clinical update, not a new trial. The authors, from the Cleveland Clinic, summarize recently published high-impact studies and guidelines on osteoporosis diagnosis and management. The abstract names four themes: international guidance on clinical use of trabecular bone score (TBS), a goal-oriented approach to treatment, new data on cardiovascular safety of romosozumab, and evidence that zoledronate is underused.

Based on the abstract, the key messages are qualitative. TBS is a tool that may add information on bone quality beyond bone mineral density, and guidelines now describe how to use it. Goal-oriented treatment means setting a target for fracture risk and choosing therapy to reach it. Emerging data address whether romosozumab, an anabolic agent with prior cardiovascular concerns, is safe for the heart. The authors also point to limited zoledronate use in early postmenopausal women and during hospitalization for hip fracture in older adults, two settings where treatment could prevent further fractures.

For clinicians, the update suggests more personalized risk stratification and a need to close the treatment gap with established, low-cost options. Patients at high risk may want to ask whether they have been formally assessed and whether treatment goals have been set.

Caveats: only the abstract was available, so details such as effect sizes, patient populations, and the strength of the cited evidence cannot be assessed. As a narrative update, it may reflect the authors' selection of studies and does not replace the full guidelines.